Apatinib and Chemotherapy Sequential Treatment With Cervical Cancer

Sponsor
Third Military Medical University
Study ID
NCT03029013
Status
Unknown

Conditions

Eligibility Criteria

Sex
FEMALE
Age
25 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Apatinib — DRUG
    Apatinib， 250 mg qd，po，after 7 days , paclitaxel (135-175 mg/m2) and platinum two drug standard chemotherapy, 21 days as a treatment cycle，during the chemotherapy of 7-21 days continue to offer the Apatinib. without disease progress, after 4 chemotherapy cycles, patients continue to accept the Apatinib maintenance treatment.

Study Details

The study is the single arm and single center clinical trials，We conduct the phase II clinical trial to further explore the efficacy and safety of Apatinib and chemotherapy sequential treatment with advanced recurrence of metastatic cervical cancer

Key Dates

Start date
Jan 31, 2017
Status verified
Jan 2017
Primary completion
Dec 31, 2019
Completion
Dec 31, 2020

Study Design

Enrollment
30 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: experimental group
    Apatinib and chemotherapy

Primary Outcome Measure

Progression free survival [ Time Frame: 24 months ]

Central Contacts

Related Studies